Gizmodo

Americans are increasingly calling poison control centers over semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy. Most of these calls appear to concern potential overdoses of semaglutide and might be tied to a rise in compounded versions of the drug, which aren’t tested for their…

Read more...

Gizmodo

New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…

Read more...

Gizmodo

If you told a person on the street in the 1970s that humans would have no base on the Moon by the year 2000, they’d probably laugh in your face. Well, it’s 2023 and we still lack even the barest of lunar infrastructure. But this week, Alenia Space and the Italian Space Agency sketched out their plans for a sustainable…

Read more...

Gizmodo

A study out this week suggests that semaglutide—the active ingredient in popular obesity drug Wegovy—might be able to help people struggling with alcohol use disorder, too. In a small sample of cases, researchers found evidence that people who took semaglutide for weight loss also experienced a significant reduction…

Read more...

Gizmodo

There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.

Read more...

Gizmodo

Health officials in Austria are the latest to warn the public to stay away from sketchy sources of semaglutide, the active ingredient in popular weight loss drugs Wegovy and Ozempic, following recent reports of severe adverse effects linked to counterfeit products. Residents have reportedly been hospitalized with…

Read more...

Gizmodo

New research suggests that Eli Lilly’s tirzepatide can boost existing efforts to lose weight. The company’s latest clinical trial found that people who dropped at least 5% of their weight before taking the drug went on to lose substantially more weight than those who took a placebo. Those in the treatment group…

Read more...

Gizmodo

Wegovy, the popular obesity treatment, also seems to offer heart health benefits. On Tuesday, Novo Nordisk reported the results of a comprehensive clinical trial evaluating the drug’s efficacy in preventing heart attacks and strokes in overweight or obese individuals. According to the company, Wegovy cut the risk of…

Gizmodo

The makers of two popular but off-label weight loss drugs are now being sued over complications allegedly linked to their use. This week, a Louisiana woman filed a complaint against the companies Novo Nordisk and Eli Lilly, arguing that they have misled patients about the risk of severe gastrointestinal side effects…